Good news from Pfizer and Moderna

Both Pfizer and Moderna have announced recently that their SARS-COV2 vaccine candidates reduce the rate of infection by over 90% in the active group compared to the control (placebo) group.

That's great news. The vaccines may turn out to be less than 90% effective when all is said and done, but even so they're likely to be far more effective than expected.

But there's other good news that might be overlooked: the subjects in the control groups did well too, though not as well as in the active groups.

The infection rate was around 0.4% in the Pfizer control group and around 0.6% in the Moderna control group.

There were 11 severe cases of COVID in the Moderna trial, out of 30,000 subjects, all in the control group.

There were 0 severe cases of COVID in the Pfizer trial in either group, out of 43,000 subjects.

The post Good news from Pfizer and Moderna first appeared on John D. Cook.